Richardson C J, Blocka K L, Ross S G, Verbeeck R K
Eur J Clin Pharmacol. 1987;32(1):89-91. doi: 10.1007/BF00609964.
Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5'-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).
对6名健康年轻志愿者口服吡罗昔康（每日1次，每次20毫克），持续15天。吡罗昔康和5'-羟基吡罗昔康的谷稳态水平分别为5.5和1.2微克/毫升。吡罗昔康的血浆半衰期（54.9小时）明显短于5'-羟基吡罗昔康（70.5小时）。稳态时血浆中未结合的吡罗昔康和5'-羟基吡罗昔康的百分比平均分别为1.10和8.07。平均25.2%的剂量以5'-羟基吡罗昔康的形式在尿液中回收；约三分之二（17.2%）为葡萄糖醛酸结合物形式。吡罗昔康的平均稳态血浆水平（Css）为7.0微克/毫升，明显高于先前报道的单剂量研究预测值（5.3微克/毫升）。
